About
Developing a femtosecond laser platform for glaucoma treatment (non-invasive laser trabeculoplasty), aiming to improve on traditional laser procedures.
HQ: US
Funding
$40M Series C (2025)
—Company profile
First femtosecond laser for the treatment of glaucoma (FLigHT), funded through a $40M Series C.
Developing a femtosecond laser platform for glaucoma treatment (non-invasive laser trabeculoplasty), aiming to improve on traditional laser procedures.
HQ: US